Prostate Cancer Clinical Trials in Detroit

Showing 321-340 of 355 trials

Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer

NCT00243048

RATIONALE: Eating a diet high in soy foods may slow the progression of some types of cancer. Isoflavones are compounds found in soy food that may slow the growth of prostate cancer cells and prevent further development of prostate cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving isoflavones together with radiation therapy may be an effective treatment for prostate cancer. PURPOSE: This randomized phase II trial is studying the side effects and how well giving isoflavones together with radiation therapy works in treating patients with localized prostate cancer.

Prostate Cancer

Barbara Ann Karmanos Cancer Institute70 participantsStarted May 2002

Detroit, Michigan, United States

TERMINATEDPhase 2< 1 mile

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

NCT00048659

The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.

Hormone-Refractory Prostate CancerProstatic Neoplasms

Astellas Pharma Inc

Anchorage, Alaska, United States • San Bernardino, California, United States • Torrance, California, United States +50 more locations

Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

Prostate Cancer Trials in Other Cities

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

Outcomes Comparison of Robotic, Retropubic, and Perineal Prostatectomy

Study On Lidocaine Vs. Placebo Pain Control During Transrectal Ultrasound Guided Prostate Biopsy

Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC

Sutent Maintenance After Response to Taxotere

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

Other Conditions in Detroit